Saturday, December 21, 2024 12/21/2024

Prebiotics to Optimize the Microbiota and Improve Outcomes of AllogeneicHematopoietic Stem Cell Transplantation

Award Number: R01HL151365
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Hematopoietic stem cell transplant (HCT) has the potential to cure leukemia and other malignant and non- malignant diseases. However, these processes are associated with significant morbidity, and treatment-related mortality (TRM) ranges from 10-30%. This is largely due to graft-versus-host disease (GVHD), in which the donor immune system attacks host tissues. GVHD has been linked to disruptions in the bacteria living in the gut (the microbiota), which in turn may be caused by factors such as conditioning chemotherapy, radiation and antibiotic treatment. GVHD and mortality are mediated by the immune system, whose activity in turn is shaped by gut microbiota. Prebiotics are nondigestible fibers that can be safely given to HCT patients and metabolized by existing bacteria in the gut to positively impact bacterial communities and metabolic products such as butyrate. Butyrate is a short chain fatty acid that is an important energy source for colonic epithelial cells and can promote regulatory T cell development, which in turn can modulate GVHD. Our preliminary data suggest that the administration of the prebiotic galacto-oligosaccharide (GOS) to mice undergoing HCT, can both increase butyrate and decrease GVHD. Here we propose the following aims: Aim 1. Evaluate the safety, tolerability, and efficacy of GOS in a phase 1 and randomized phase 2 trial. Aim 1A: We will determine the maximum tolerated dose (MTD) of GOS in a phase 1 dose escalation study (Years 1-2). We hypothesize that GOS is tolerable in doses that increase bacterial diversity and butyrate levels. Aim 1B: We will evaluate the impact of GOS on HCT outcomes in a randomized placebo-controlled phase 2 trial. (Years 2-5). We hypothesize that patients receiving GOS will have better outcomes including decreased grade II-IV GVHD. Aim 1C: We will compare the pre-HCT microbiome of GOS responders (those who received GOS in the phase 1 and phase 2 trials and had increased bacterial diversity) and non-responders (those with no change or decreased bacterial diversity) to determine elements of the pre-HCT microbiome that may be associated with GOS response. Aim 2. Evaluate the impact of GOS on biomarkers of intestinal and systemic inflammation and GVHD as potential mediators of HCT outcomes. The regenerating islet-derived protein 3 alpha (REG3A), is of particular interest. REG3A is an antimicrobial peptide that may be affected by the microbiota and has been reported as a biomarker of GVHD. We hypothesize that patients treated with GOS will have positive changes in biomarkers of inflammation and GVHD (increased REG3A, primary endpoint). As an exploratory aim, biomarkers will be studied for their associated with prebiotic interventions, changes in the microbiome, bacterial metabolites, immune reconstitution, and HCT clinical outcomes (GVHD, TRM, OS). Our long-term goal is to understand how prebiotic interventions impact the microbiota and bacterial metabolites and use prebiotics to decrease inflammation and improve HCT outcomes. We expect that the data generated from this study will lead to future clinical trials, including a multicenter randomized phase 3 trials, or to microbiota-based diagnostic assays to personalize therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $348,750 )
2024	2024	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Blood Diseases and Resources Research	001	5	9/11/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$348,750
2024	2023	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Blood Diseases and Resources Research	000	4	9/10/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $348,750

Issue Date FY: 2023 ( Subtotal = $362,250 )
2023	2023	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Blood Diseases and Resources Research	000	4	7/7/2023	NON-COMPETING CONTINUATION	$362,250
														Subtotal = $362,250

Issue Date FY: 2022 ( Subtotal = $362,250 )
2022	2022	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Blood Diseases and Resources Research	000	3	7/8/2022	NON-COMPETING CONTINUATION	$362,250
														Subtotal = $362,250

Issue Date FY: 2021 ( Subtotal = $362,250 )
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Blood Diseases and Resources Research	001	2	7/16/2021	NON-COMPETING CONTINUATION	$362,250
2021	2020	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Blood Diseases and Resources Research	000	1	7/15/2021	NEW	$0
														Subtotal = $362,250

Issue Date FY: 2020 ( Subtotal = $362,250 )
2020	2020	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Blood Diseases and Resources Research	000	1	6/25/2020	NEW	$362,250
														Subtotal = $362,250

Grand Total All Awards = $1,797,750

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prebiotics to Optimize the Microbiota and Improve Outcomes of AllogeneicHematopoietic Stem Cell Transplantation

Award Number: R01HL151365

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer